tively. A total of 1068 people from a Danish family collection comprising 138 Type I diabetic sib-pair families (289 affected and 121 unaffected offspring) and 103 Type I diabetic parent-offspring multiplex families (103 affected and 112 unaffected offspring) were typed for the three most frequent polymorphisms with high heterozygosity indices and for a FAS microsatellite. Haplotypes were established and data analysed using the extended transmission disequilibrium test, ETDT. Conclusion/interpretation. We found no overall evidence for linkage of the FAS polymorphisms to Type I diabetes. We conclude that it is unlikely that the Fas gene does contribute to genetic susceptibility for Type I diabetes. [Diabetologia (2000) 43 : 800±808] Keywords Genetics, candidate gene, apoptosis, tolerance, microsatellite, ALPS, c-Myb, SP-1, NF-kB.
expressed on the surface of many types of cells, such as lymphocytes, fibroblasts, epithelial and certain endothelial cells [7] . Signalling by Fas leads to apoptotic cell death. Apoptosis can be induced by the T-cell effector ligand, FasL, through binding to Fas. Apoptosis mediated by Fas/FasL has a pivotal role in peripheral lymphocyte homeostasis both in activation induced cell death in the down regulation of an immune response and in peripheral clonal deletion of autoreactive T-lymphocytes [8] .
The human FAS has nine exons spanning 26 kb [9, 10] and maps to chromosome 10q24.1 [11] . A number of rare heterozygous mutations in the human FAS associated with autoimmune lymphoproliferative syndrome (ALPS) (a disorder of lymphocyte homeostasis and immunological tolerance) have been described in which the genotype influences the penetrance of ALPS [12, 13] .
Apoptosis mediated by Fas could be altered in Type I diabetes both on the T-cell and beta-cell level and have a role in the development of human Type I diabetes. In the immune system, the expression of Fas on T-lymphocytes and B-lymphocytes is reduced in humans with preclinical and clinical Type I diabetes [14] . Human pancreatic beta cells do not constitutively express Fas, but after treatment with IL-1b in vitro, Fas expression is observed on isolated human beta cells [15, 16] . Pancreas biopsy specimens from recent-onset Type I diabetic patients showed Fas expression on beta cells and FasL expression on islet infiltrating T-cells [17] . Beta cells from newly diagnosed diabetic patients expressed Fas on their surface, showing extensive apoptosis possibly mediated by FasL-positive T-lymphocytes [18] .
Further, gene variations with quantitative effects on Fas expression could contribute to the breakdown of peripheral tolerance and Type I diabetes.
We therefore screened the entire human FAS for mutations by single strand conformational polymorphism (SSCP)-heteroduplex analysis. We tested the polymorphisms found with a high heterozygosity index for linkage in a Danish Type I diabetic family collection. We also tested a FAS microsatellite marker [19] localised 48.5 kb within the human FAS for linkage as an additional marker.
Subjects and methods
Subjects. Material for the SSCP-heteroduplex analysis was provided by 20 unrelated Danish Caucasian Type I diabetic patients and 10 healthy Danish Caucasian males.
The material for the linkage analysis was obtained from 1068 people of which 647 came from 138 Danish Caucasian sib-pair Type I diabetes mellitus multiplex families, with 289 Type I diabetic offspring (133 females), and 121 (62 females) non-affected offspring. Both parents in 99 families and 1 parent in 39 families were available for genotyping. All index cases, defined as the first affected offspring (68 females/ 70 males), had onset of Type I diabetes before age 30 years (mean ± SD: 10.0 ± 5.5 years). The other 421 subjects were from 103 Danish Caucasian parent-offspring multiplex families, characterised by at least 1 parent and only 1 offspring affected with Type I diabetes. Both parents, all 103 affected (53 females) and 112 unaffected (55 females) offspring were genotyped. All affected offspring had onset of Type I diabetes before age 30 years (mean ± SD: 10.0 ± 4.8 years). All families were unrelated.
The material for the determination of allele frequencies for the new promoter mutations comprised the 240 Danish Caucasian Type I diabetes index cases and 77 healthy Danish Caucasian males. Ethical approval was obtained from the ethics committee of Copenhagen County.
Screening for and identification of mutations in the human FAS. Oligonucleotide sequences for PCR amplification of the human FAS promoter, exons 1±9 with adjacent intron borders and the 3 ¢ untranslated region (3¢ UTR) of the human FAS were designed from the genomic human FAS sequence [10] (GenBank AC X82279-X82286) to generate 26 overlapping PCR products 212±300 bp long (Table 1) with an average overlap of 52 bp between segments.
Polymerase chain reaction (PCR) amplification of genomic DNA was done with the primers listed in Table 1 and 150 ng DNA as a template. The assay conditions were as follows: primers 0.5 mmol/l each, deoxyribonucleoside triphosphates (dNTPs) 100 mmol/l, MgCl 2 0.5±2.0 mmol/l, Taq DNA polymerase (Promega, Madison, Wis., USA) 0.5 U/sample with 1´reaction buffer, all in final concentrations in a reaction volume of 40 ml.
The cycling conditions were 94°C for 3 min, followed by 30±35 cycles: 95°C for 45 s, annealing (varying between 48 and 64°C for different primers) for 45 s and extension at 72°C for 2 min 30 s, followed by a final extension at 72°C for 10 min.
For the SSCP-heteroduplex analysis [20, 21] of the human FAS we used the 26 overlapping PCR amplicons listed in Table 1, and the Gene Gel Excel 12.5/24 Kit / GeneGel Clean 15/ 24 Kit with the PhastSystem (Amersham Pharmacia Biotech, Uppsala, Sweden). Briefly, after the PCR amplification 4 ml of the reaction mixture from each sample were mixed with 4 ml of denaturing buffer (99 % formamide, 1 % xylene cyanol, 20 mg bromophenyl blue). The samples were denatured at 95°C for 5 min, chilled on ice for 10 min to allow heteroduplex formation and then loaded onto non-denaturing polyacrylamide gels (15 % and 12.5 %, respectively) with or without 1 % glycerol. Samples were run on the GenePhor Electrophoresis Unit (Amersham Pharmacia Biotech) with 15 W, 25 mA at 5°C for the excel gels and 9 W, 15 mA at 15°C for the clean gels containing 1 % glycerol. Gels were stained using the Plus One DNA Silver Staining Kit (Amersham Pharmacia Biotech) on a Hoefer Automated Gel Stainer (Pharmacia Biotech, San Francisco, Calif., USA). Samples showing mobility shifts or heteroduplex formation were sequenced using cycle sequencing.
For cycle sequencing 30 ml of PCR product from samples showing mobility shifts or heteroduplex formation were sequenced using the PCR product pre-sequencing kit and the Thermo Sequennase Cycle Sequencing Kit (both Amersham Pharmacia Biotech, Cleveland, Ohio, USA) according to the manufacturer's instructions. Primers (Table 1) were labelled with g 33 P using T4 polynucleotide kinase (Promega) according to the manufacturer's instructions.
Samples were run on 6 % polyacrylamide gels. Gels were dried and exposed to x-ray films.
Restriction enzymes for PCR-based RFLP. The PCR amplicons (Table 1) were digested with the following restriction enzymes: FAS microsatellite. Primer sequences (primers 1/2) are shown in Table 1 [19] . Using biotinylated primers we typed the FAS microsatellite by PCR of 40 ng genomic DNA template followed by PAGE, blotting and made visible with a streptavidin-peroxidase catalysed enzyme-derived chemiluminescence (ECL) reaction. Cycling conditions were: 94°C for 3 min, 30 cycles of: 95°C for 30 s, 52°C for 30 s and 72°C for 30 s, followed by a final extension at 72°C for 10 min. We added 20 ml stop buffer (98 % formamide) to 20 ml of the PCR product, heated it for 2 min at 94°C and placed it on ice. We ran 6 ml of this mixture on a 6 % polyacrylamide gel at 65 W. The PCR products were then transferred to a positively charged nylon membrane Hybond-N + (Amersham Pharmacia Biotech, USA) and UV cross-linked (UV Stratalinker 2400; Stratagene, La Jolla, Calif., USA). The membranes were developed using the Streptavidin-HRP, S-5512 (Sigma, St. Louis, Mo., USA) and ECL gene detection reagents (Amersham Pharmacia Biotech, USA) and exposed to x-ray films for 1±5 min [22] . Samples homozygous for the different alleles were confirmed by sequencing on an ABI PRISM 310 DNA sequencer system (Perkin Elmer, Foster City, Calif., USA).
MatInspector. To asses for potential DNA binding sites in the human FAS promoter for various transcription factors we used the MatInspector program [23] .
Statistical analysis. Transmission disequilibrium test (TDT) for linkage [24] and intrafamilial association [25] and extended transmission disequilibrium test (ETDT) for linkage with multiallele markers were carried out [26] . We considered differences significant at p less than 0.05. Linkage disequilibrium was calculated as the disequilibrium coefficient, D [27] .
Results

Molecular scanning of the human FAS by SSCPheteroduplex analysis
A complete molecular scanning of the entire human FAS (promoter region, exons 1±9, exon-intron borders and the 3¢ UTR) was carried out using SSCPheteroduplex analysis and direct sequencing in 20 Type I diabetic patients and 10 healthy control subjects. We identified 15 mutations ( Table 2 , Fig. 1 ), of which 4 have been described previously [28, 29] .
In the promoter region we found eight mutations. Of these a g-1194A®T and a g-295A ins give rise to alterations of transcription factor binding consensus sequences for c-Myb, SP-1 and nuclear factor-kB (NF-kB), respectively. We confirmed the silent g250A®G in codon 58 (ACA) and the silent g154C®T in codon 198 (ACC) described in [28] .
Linkage analysis
FAS. The TDT [24] was applied to analyse linkage between the g-690T®C, the g-670G®A polymorphisms in the FAS promoter and the g154C®T polymorphism in codon 198 and Type I diabetes. The parental heterozygosity indexes were 0.26, 0.51 and 0.39, respectively. We found no evidence for linkage between any of the three polymorphisms and Type I diabetes (p = 0.55, p = 0.91 and p = 0.84, respectively, Table 3 ).
The ETDT for multi-allele marker loci [26] was used to analyse for linkage between haplotypes established from the two FAS promoter polymorphisms, haplotypes established from the above three loci in the Fas gene and Type I diabetes. The heterozygosity indexes of the parents were 0.62 and 0.72 for the FAS promoter haplotypes and the three loci haplotypes, respectively. There was no evidence for linkage to Type I diabetes, [allele-wise TDT: FAS promoter For the FAS three loci haplotypes, we also tested for intrafamilial association [25] by considering the transmission of different haplotypes to index cases and observed skewed transmission of the CAC haplotype (Table 5 ) with a transmission frequency of 61 % of this haplotype to index cases. This was not, however, statistically significant (p value, uncorrected = 0.08, p value, corrected = 0.75).
FAS microsatellite. We also typed the Danish family collection for a FAS microsatellite (CA repeat polymorphism) located within 48.5 kb of the Fas gene on chromosome 10q24.1 (Table 1 ; primers 1/2) [19] . The microsatellite marker was highly polymorphic, with 10 alleles observed, ranging from 17 to 26 CA repeats and a heterozygosity index of 0.83 in the parents (Table 6). The extended transmission disequilibrium test (ETDT) for multi-allelic marker loci [26] was used to analyse for linkage between the FAS microsatellite and Type I diabetes. All affected offspring were considered. There was no evidence for linkage to Type I diabetes, (allele-wise TDT p = 0.53, Table 7 ).
Linkage disequilibrium. The disequilibrium coefficients, D, for the g-690T®C and g-670G®A, for the g-690T®C and the g154C®T, for the g-670G®A Table 2 . Mutations in the human FAS; promoter, exons 1±9 including exon-intron boundaries and the 3'UTR region 
and the g154C®T, for the g-690T®C and the FAS microsatellite, and for the g154C®T and the FAS microsatellite were ±0.04, ±0.03, 0.11, 0.03 and 0.02, respectively. Between the g-690T®C and the FAS microsatellite and between the g154C®T and the FAS microsatellite, 5 % recombinatory events occurred.
Discussion
We have completed a molecular scanning of the entire human FAS identifying 11 new mutations and confirming four described previously. We found eight mutations in the promoter region where several of these could affect interesting transcription factor binding sites. The promoter mutations are numbered relative to the start codon. The g-1377G®A polymorphism in the silencer region has been described previously [29] and could affect the SP-1 binding site [30] . We tried unsuccessfully to establish a mutagenically separated PCR assay [31] to type the family collection for this polymorphism. In the enhancer region of the human FAS we identified a new g-690T®C polymorphism and confirmed a g-670G®A polymorphism [29] . The new g-690T®C polymorphism results in a missing restriction site for NdeI. The g-670G®A polymorphism, resulting in a missing restriction site for MvaI, abolishes the consensus binding site, ATTCCAGAAA [32] , for the nuclear tran- scription element gamma activation site (GAS) important in interferon (IFN)a and IFNg signalling. We identified new mutations only present in the Danish Type I diabetic families and not in healthy control subjects. Of the mutations two, a g-1221C®G and a g-1194A®T, were in complete linkage disequilibrium with each other. The g-1194A®T is in a c-Myb binding site sequence, AAC(G/T)G, where the A is essential for binding of the transcription factor [33] and results in a new restriction site for AccI. It has been shown that c-Myb is a direct transcriptional activator of the human FAS promoter [10] . The allelic frequency in 240 unrelated Type I diabetic patients for the mutant allele was 0.006. The mutant allele was not present in 77 healthy control subjects. We also identified a new g-295Ak ins which occurs at a composite binding site for both the SP-1 and NF-kB transcription factors at ±295 to ±286 required for activation-driven Fas up regulation [34] . These two transcription factors compete for this binding site. In resting peripheral blood lymphocytes Fas expression is low and SP-1 is bound to this site. In activated lymphocytes, as a response to NF-kB heterodimer binding, Fas expression is up regulated. The allelic frequency in 240 unrelated Type I diabetic patients for the mutant allele was 0.01. The mutant allele was not present in 77 healthy control subjects.
We found no evidence of linkage between any of the polymorphisms identified in the human FAS and Type I diabetes.
Haplotypes were established from the two polymorphisms in the promoter (the g-690T®C and the g-670G®A) and the g154C®T polymorphism in exon 7. As a test for intrafamilial association [25] we considered the transmission of haplotypes to index cases in the diabetic families and found a skewed transmission of the CAC haplotype with 61 % transmitted to index cases.
The risk that we might have overlooked mutations in the human FAS, which could be linked to Type I diabetes, is minimal. Thus, the sensitivity and the specificity of the SSCP-heteroduplex analysis in our laboratory was high, 93 % and 92 %, respectively compared with a sensitivity in the range of 70±90 % reported by others [20] . We have also sequenced 15 out of the 26 PCR amplicons equal to approximately 58 % of the human FAS in a minimum of four subjects. The remaining nine amplicons showed no polymorphic patterns in the SSCP-heteroduplex analysis. Minor susceptibility genes are expected only to modify risk, hence they are likely to be frequent in the general population. In the power estimates we have assumed a 12.5 % deviation [35] . The probability of making a type II error of the 5 % probability level in our statistical analysis of the MvaI and the DraI polymorphisms is low (~14 % and 24 %, respectively) because the power is relatively high due to the many transmissions observed. Based on the percentage of parents heterozygous for the NdeI, the MvaI and the DraI polymorphisms it was expected that about 161, 316 and 241 transmissions to affected offspring could be observed for the polymorphisms, respectively. The risk for a type II error for the NdeI polymorphism was about 43 %.
Finally, we also tested a FAS microsatellite, localised within 48.5 kb of the human FAS, for linkage to Type I diabetes in the Danish families. The FAS microsatellite is close to the human FAS and was a priori considered a good marker for FAS unless there was a mutational ªhotspotº situated between them. The microsatellite was highly informative with ten alleles observed and a heterozygosity index in the parents of 0.83. We found no evidence for linkage to Type I diabetes for the FAS microsatellite which correlates well with results for the polymorphisms in the gene proper. Linkage disequilibrium analysis showed, however, that the FAS microsatellite is not in linkage disequilibrium with the polymorphisms identified in FAS. Hence, this microsatellite is possibly not a good marker for FAS. Furthermore, no evidence for linkage between the FAS microsatellite and Type I diabetes was found in an Australian sib-pair family data set [19] .
A genome-wide linkage study showed linkage between chromosome 10p13-p11 and Type I diabetes [5] , a region not including FAS. IDDM17 (a Type I diabetes susceptibility locus described in a Bedouin Arab pedigree) maps to chromosome 10q25 [36] . FAS maps just outside this region (personal communication, C. F. Verge).
In murine models of Type I diabetes, pancreatic beta-cell death mediated by T-cells during the course of diabetes is mainly by apoptosis [37±39]. There is conflicting evidence for the role of Fas-mediated apoptosis in the development of diabetes in the nonobese diabetic (NOD) mouse [40±45] .
We have scanned the entire human FAS (promoter region, exons 1±9, exon-intron borders and the 3 ¢UTR region) by SSCP-heteroduplex analysis and have identified a total of 15 mutations, of which 4 have been described previously. In the promoter region we identified several mutations, which could alter the consensus sequence for the SP-1, c-Myb, GAS and NF-kB transcription factors. These polymorphisms could be relevant for the understanding of genetic susceptibility to other immunological disorders. We found, however, no evidence for linkage between individual polymorphisms or constructed haplotypes from polymorphisms from three loci in the human Fas gene or a FAS microsatellite and Type I diabetes in a large Danish, Caucasoid Type I diabetic family collection.
